Nuformix Research Results News
Nuformix Publishes Positive Fibrofind Results
![](/fibrosislab/newsandevents/nuformixresearchresultsnews/banner-1-300x112.jpg)
On January 31st, Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.
This pilot study has been performed by FibroFind the University-based service facility embedded in Newcastle Fibrosis Research Group
Click HERE to download the report published by Nuformix
![](/media/sites/training/drummond/images/newsandevents/nuformixnewsjan2018/NFX_wide.png)
![](/media/sites/training/drummond/images/newsandevents/nuformixnewsjan2018/FibroFind_logo_strapline.jpg)
Last modified: Tue, 13 Feb 2018 14:52:13 GMT